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1 Introduction 
 
A high workload for ophthalmologists and long waiting lists for patients challenge the 
organization of ophthalmic care. Tasks that require less specialized skills, like the 
monitoring of stable (well controlled) glaucoma patients could be substituted from 
ophthalmologists to other professionals (substitution in person). In addition, care 
could perhaps be provided in an ambulatory setting (substitution in location of care). 
To date, little is known about substituting care in ophthalmology, the organizational 
and professional dynamics involved and any consequences for both the quality of 
care and cost effectiveness.  
 
Glaucoma is the name given to a group of eye diseases characterized by damage to 
the optic nerve yielding gradual, irreversible loss of visual field. Glaucoma is often 
related to too high an intraocular pressure (IOP) and is age related. The usual care 
for glaucoma patients consists of diagnosis, lifelong monitoring, and treatment and is 
provided by ophthalmologists. However, monitoring stable glaucoma patients will 
presumably not require the specialist expertise of an ophthalmologist and may be 
carried out by less specialized professionals. Therefore, the quality of care given to 
stable glaucoma patients was evaluated when provided by ophthalmic technicians or 
optometrists based on pre-set protocols and under supervision of ophthalmologists in 
a Glaucoma follow-up unit (GFU) within The Rotterdam Eye Hospital (REH). 
 
The objective of this study is to evaluate an organizational intervention, a GFU for 
monitoring stable glaucoma patients in a hospital setting, staffed by non-physician 
Health Care Professionals instead of ophthalmologists. Furthermore, conditions will 
be formulated that need to be fulfilled to successfully substitute the monitoring care 
for stable glaucoma patients to a primary care optometrist (substitution in person as 
well as in location). The conditions will be based on the experiences with the GFU 
(substitution in person only).  
 
Research questions to be answered are:  
1. What are the effects of the GFU on the quality of care, on patient satisfaction and 
on the satisfaction of health care providers (HCPs) involved, compared to usual 
care? Is the care delivered in the GFU at least equivalent to the care provided by 
ophthalmologists?  
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2. What are the costs of the ophthalmologists' usual care, versus those of the care 
provided by the GFU, for the patient, the hospital, the health care system and the 
society?  
3. Which conditions need to be fulfilled (about both quality and costs) to eventually 
succeed in implementing glaucoma monitoring care for stable patients by 
optometrists in a primary care setting? 
 
 
1.1 Realisation study aim and research questions 
 
During this study, the GFU was compared with usual care based on the quality of 
care, the satisfaction of patients, the satisfaction of the HCPs and costs. Additionally, 
interviews with stakeholders gave us information about the conditions that need to be 
fulfilled in order to successfully implement glaucoma monitoring for stable patients by 
optometrists in the primary care setting. 
All objectives have been achieved and all research questions could be answered. 
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2 Methods  
 
To answer the respective research questions, we undertook the following studies:  
1. Randomised Controlled Trial (RCT) and a process evaluation  
2. Cost-effectiveness analysis  
3. Feasibility study  
 
 
2.1 The RCT 
 
2.1.1. Main outcome measures 
The main outcome measures of the RCT were (1) Quality of care: compliance of the 
GFU employees to the standard working protocol; frequency and results of 
examinations performed; treatment changes; (2) Patient experiences: the overall 
mark given for the care delivered; information about the visit; visit expectations; 
knowledge of the HCP; opinion about the waiting area. 
 
2.1.2. Details of study population 
1) Patients were those with stable glaucoma as assessed by a glaucoma specialist 
(follow-up visit scheduled for 6 months or more) and patients who are at risk for 
developing glaucoma.  
2) HCPs were ophthalmologists specialised in glaucoma, ophthalmic technicians, 
hospital optometrists. 
 
2.1.3. Patient selection and Randomisation 
Patients who visited a glaucoma specialist or who visited the GFU between 
September 2005 and April 2006 were considered eligible for inclusion. The manner 
of patient selection differed depending on whether the patient visited the glaucoma 
specialist or the GFU before inclusion.  
(1) Glaucoma specialist: Once the glaucoma specialist decided during a visit that the 
patient was suitable for the GFU, he explained the RCT to the patient. After the visit, 
the medical record of the patient was sent to a member of the study team, who first 
assessed whether the patient met the inclusion criteria. If this was the case, the 
patient was randomly allocated to a treatment group using a randomisation table. 
After randomisation an appointment was made. The patient received the time and 
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date of the appointment together with written information about the trial by regular 
mail.  
(2) GFU: The GFU started late 2004. Because the clinics of the GFU were fully 
occupied by patients by September 2005, we decided to include these patients. 
Before every GFU clinic, scheduled between September 2005 and April 2006, a 
member of the study team collected the medical records and assessed which 
patients were eligible for inclusion. The eligible patients were randomly allocated to a 
treatment group using the same randomisation table as with the glaucoma 
specialist’s patients. The medical records were then given back to the HCP of the 
GFU. During the visit, the HCP explained the RCT to the patient and gave the patient 
written information. Patients assigned to the glaucoma specialist treatment group 
were given a new appointment with the referring glaucoma specialist. Patients 
assigned to the GFU treatment group and willing to participate were given a patient 
questionnaire and their medical records were sent to the member of the study team 
who collected the relevant data.  
The two treatment groups were balanced for 2 predetermined stratification variables: 
the referring glaucoma specialist, and the time to the next scheduled visit, being 
either ≤ 6 months or > 6 months. 
 
2.1.4. Inclusion criteria 
To be eligible for the study, patients had to meet the following criteria:  
(1) the patient was referred to the GFU by a glaucoma specialist of the REH;  
(2) the patient had a diagnosis of glaucoma in one or both eyes or had a risk factor 
for glaucoma, i.e. high IOP and / or a positive family history;  
(3) the optic disc, macula, and the fundus periphery were examined;  
(4) the next scheduled visit of the patient was in ≥ 6 months;  
(5) the target pressure (TP) of the glaucoma patients was noted in the medical 
record. The TP of patients with a risk factor for glaucoma was, by default, ≤ 30 
mmHg, unless other risk factors called for an explicitly lower TP;  
(6) the actual ophthalmic medication was written in the medical record;  
(7) the patient’s Snellen visual acuity in each eye equalled ≥ 20/100 and/or the 
patient had no loss in the central visual field, as measured by a Humphrey Field 
Analyser, standard 24-2 test algorithm (HFA 24-2; Carl Zeiss Meditec, Dublin, CA, 
USA)  
(8) the patient had no other significant ocular disease;  
(9) the patient had not undergone laser therapy for diabetic retinopathy;  
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(10) the patient had a refractive error between + 5 and – 8 dioptres (spherical 
equivalent). 
  
2.1.5. Patient Visits 
The care provided in the GFU, the back referral criteria to the glaucoma specialist, 
and the ‘care as usual’ (glaucoma specialist group) are described in Table 1. 
 
Activity Glaucoma specialist GFU Criteria for back referral 
1. short history  every visit every visit  
2. IOP*  every visit every visit IOP > Target Pressure 
3. Snellen visual 
acuity  
as required, minimally 
once yearly  
every visit 
 
decline in visual acuity of ≥ 2 lines 
4. optic disc 
assessment 
every visit never  
5. GDx ECC**  at doctor’s request 
(approx. once yearly) 
every visit - suspicion of progression 
- in case of 1st GDxECC; NFI > 35 
and/or left/right asymmetry and/or 
local defect 
6. HFA 24-2***  at doctor’s request 
(approx. once yearly) 
- once a year in 
moderate to advanced 
visual field damage****  
- at doctor’s request 
suspicion of progression 
7. overall judgement  every visit every visit  
8. timing of the next 
appointment 
every visit every visit  
9. medical 
prescriptions 
every visit every visit  
* Intraocular pressure by applanation tonometry 
** GDx ECC (Carl Zeiss Meditec, Dublin, CA, USA) scanning laser polaritmetric 
images 
*** Humphrey Field Analyser, standard 24-2 test algorithm (HFA 24-2; Carl Zeiss 
Meditec, Dublin, CA, USA) 
**** Criteria moderate/severe visual field damage: the mean deviation (MD) of the 
last performed visual field was ≤ - 5dB 
  
2.1.6. Data collection  
To obtain quantitative data to investigate the quality of care, a member of the study 
team filled in a Case Report Form (CRF) after each patient visit using the relevant 
information form the medical record. A different member of the study team checked 
the CRF before entering it into the computerized system.  
A patient questionnaire was designed to score the patients' experiences with the care 
they received. It addressed the following issues: general/overall satisfaction, 
courteousness of professionals, HCP/patient communication, professionalism, ease 
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and time to get an appointment, and some basic questions related to costs (i.e. 
travelling time, travelling costs).  
This was an existing questionnaire, which was previously tested for validity and 
reliability1, supplemented with relevant patient cost questions. It was given to the 
patients after each visit. 
The accuracy of the data was monitored regularly by selecting random samples of 
CRFs and patient questionnaires and then comparing the data entered into the 
computerized system with the original forms. 
 
2.1.7. Statistical Analysis 
To investigate whether there were differences between the treatment groups at 
baseline and during the study period, we used independent T-tests. When there was 
no normal distribution we used a chi-square test and Mann-Whitney for independent 
groups and the Wilcoxon signed rank test for dependent groups. All statistical tests 
were two sided and were performed at the 5% significance level 
 
 
2.2 Process evaluation 
 
During the study period, the working processes and implementation of the GFU were 
carefully monitored. We focused on organizational changes and on changes in the 
functioning of the GFU after implementation 
The process evaluation consisted of a content analysis of relevant documents, 15 
semi-structured interviews with the involved employees (i.e. glaucoma specialists, 
and employees of the GFU), and a logbook with observations was kept by the 
primary researcher.  
 
 
2.3 Economic Evaluation 
 
We performed a cost-effectiveness analysis from four perspectives to answer the 
second research question. In patients with glaucoma, a difference in health outcomes 
between the GFU and the ophthalmologist group was not expected in the current 
study, because of the slowly progressive nature of this disease. Therefore, the costs 
will not be related to health outcomes, but costs and quality of care outcomes will be 
linked in the overall results. In case the quality of care is equal for the usual 
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ophthalmologist care and that of the GFU, the economic evaluation becomes a cost 
minimization analysis. 
The perspectives used were those of the patient, the eye hospital, the health care 
system and the societal perspective.  
In any economic evaluation three steps are necessary to estimate the costs:  
1. identification of the relevant cost items;  
2. measurement of the utilization per item: the estimated amount of consumption (or 
time);  
3. valuation of the cost items: determining the costs per unit (e.g. a visit to an 
optometrist)  
 
2.3.1. Identification  
The following relevant cost items were identified by interviews:  
• health care cost of visits to the ophthalmologist;  
• health care cost of visits to the GFU;  
• health care cost of referral visits to ophthalmologists;  
• health care cost of visits to the perimetry department for the GDx and HFA; 
• health care cost of medication; 
• health care cost of surgery related to glaucoma (including laser therapy); 
• cost of patient time related to all types of visits; 
• travelling costs related to the visits; 
• implementation costs of the GFU.  
 
2.3.2. Measurement  
During the trial, the number of visits and the medical procedures performed during 
each visit were recorded for each patient in a CRF. The durations of these visits were 
measured in a sample of these visits. If the GFU HCPs needed more (or longer) 
consultations to establish the same effectiveness, this would then be observed.  
Every visit, glaucoma patients were given a questionnaire that we developed to 
report their travelling distance, mode of transport, travelling time, waiting time and 
working status, in order to calculate the travelling and time costs for patients in case 
of hospital care.  
The proposed substitution of care to the GFU required organizational changes and 
hence implementation costs within the hospital. The most important changes were 
the initial and structural training of the employees of the GFU, writing the standard 
treatment protocol, additional supervision and monitoring by ophthalmologists. To 
collect this information, HCPs at the GFU, as well as the ophthalmologists were 
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interviewed. These costs were added to the costs of a GFU visit as implementation 
costs for the GFU.  
 
2.3.3. Valuation  
All costs were calculated for 2007. The total costs for each type of eye care visit were 
calculated, including personnel costs, administrative costs, cost of equipment and 
overhead costs, using our cost estimates based on data provided by the financial 
administration of the REH. The calculations were done according to the CVZ (The 
Health Care Insurance Board) costing guidelines and previous research in the 
REH2,3. We used information on costs per unit as produced for the internal budget 
allocation of the REH. Location costs, interest and costs of medical specialists are 
included in this information. Only for the costs of non-laser operations, another 
method was used. The DBC price (a fixed reimbursement rate for a specific 
diagnosis related therapy) in 2007 was used as a proxy of the real costs, because of 
the probable transfer of the reimbursements of glaucoma care from the so-called A-
segment to the B-segment in 2009. Details of this transfer are outside the scope of 
the current project. 
Relevant items from the CVZ costing guidelines4, were updated and used for the 
calculation of patient time costs per hour and travelling costs per kilometre. As the 
implementation costs were dominated by personnel input, personnel costs per hour 
was the relevant valuation component.  
If appropriate, missing values were replaced by values known from other visits of the 
same patient. In all other cases, the data from a comparable group of patients were 
imputed to the missing values. 
 
2.3.4. Cost results  
For both treatment options, the total number of visits (per type) was aggregated for 
all patients and combined with the costs per unit to derive the total health care costs 
of all visits. We calculated the patient costs using the information of the patient 
questionnaires combined with the updated time and travelling costs per unit of time 
and per kilometre.  
The implementation costs were calculated as a combination of the additional time 
investments of all types of personnel as described above multiplied with their 
respective personnel costs.  
The initial implementation costs that were only made before starting the GFU, were 
spread over 5 years. The structural costs per year were added to the initial 
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implementation costs per year. The implementation costs per visit were based on the 
number of visits in 2007 (1598).  
The costs have been expressed as average costs per patient per study year and 
average costs per patient. 
 
2.3.5. Statistical analysis 
We used SPSS 15.0 to analyse the data. Since all cost variables were not distributed 
normally, we performed the parametric Mann-Whitney U-test to compare the two 
treatment groups. 
 
 
2.4 Feasibility study 
 
As mentioned previously, the GFU was considered as an intermediate step towards 
transferring the monitoring of stable glaucoma patients out of the REH. The ultimate 
aim was to refer stable glaucoma patients and patients at risk for developing 
glaucoma to primary care optometrists (i.e., a twofold substitution, both in person and 
in location). There were two motives for this twofold substitution. First, key 
stakeholders assumed that substitution would decrease the workload of the 
physicians and waiting lists for patients. Secondly, it would enforce the relationship 
between primary care optometrists and the REH, which might consolidate or even 
expand the number of patients consulting the REH in the future. 
During the RCT and costing study it became clear that transferring the monitoring of 
stable glaucoma patients towards ophthalmic technicians (i.e., substitution in person) 
is probably as safe and effective as the normal monitoring by ophthalmologists. This 
preliminary outcome supported the idea of exploring the feasibility of transferring the 
care for this group of patients out to primary care optometrists (i.e., substitution in 
person and in location). 
 
We conducted a qualitative study to explore the feasibility of the substitution of care 
to primary care optometrists, organizationally unified in the so-called Optometristen 
Collectief Rijnmond (OCR). The OCR already collaborates with the REH. The study 
consisted of a content analysis of relevant documents (e.g., annual reports, policy 
briefs) and of 27 semi-structured interviews with a purposeful sample of all 
stakeholders involved: ophthalmologists, optometrists, hospital managers, healthcare 
insurers, the Dutch Healthcare Authority and patients (see Table 2). The data 
gathered was analysed against a theoretical framework using theories on 
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professionalism, hospital management, quality systems and applied political analysis 
5,6. If the results of the feasibility study show that substitution of care to primary care 
optometrists is possible the willingness to accept by the primary care optometrist will 
be explored.  
 
Table 2. Stakeholders interviewed 
Stakeholder Number Clarification 
Management of the Rotterdam Eye 
Hospital (REH) 
4 
 
CFO, CEO, Manager of the Eye Care Network, 
Advisor concerned with optometry relations 
Ophthalmologists 4 All 4 glaucoma specialists of the REH 
Primary care optometrists 
 
 
6 
 
 
4 were self-employed, 2 worked in an optic store 
chain, 5 participated in the Optometristen 
Collectief Rijnmond  
HCPs of the GFU 5 1 optometrist and 4 ophthalmic technicians 
Patients 
 
 
5 
 
 
1 representative of the Dutch Glaucoma Patient 
Association, 4 participated in the RCT: 1 in the 
arm of the specialist and 3 in the GFU arm 
Healthcare insurers 
 
2 
 
Two representatives of the major health insurers 
in the Rotterdam region 
The Dutch Healthcare Authority (Nza) 1 Senior policy advisor  
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3 Results 
 
3.1 The RCT 
 
The enrolment of patients began in September 2005 and ran through March 2006. A 
total of 866 patients were included. There were no significant demographic or clinical 
imbalances between the treatment groups (Table 3). 51 patients (6%) did not visit the 
REH in the study period. Of these, 30 patients were no shows, 14 moved their 
appointment to a date after the data collection ended, 2 underwent cataract surgery 
and had no glaucoma related appointment in the study period. The exclusion of these 
patients did not lead to any significant differences between the treatment groups. The 
only difference between the excluded and included patients was their follow-up time. 
The follow-up time is the time the glaucoma specialists write in the medical records 
for a next appointment. The excluded patients (10.9 months, SD ± 2.3), had a 
significantly longer follow-up time compared to the included patients (9.6 months, SD 
± 2.9, sig. 0.001).  
We collected information from 2100 visits brought by 815 patients. The average time 
between visits was 8.8 months, SD ± 4.0. There were no differences between the 
treatment groups. 
 
Table 3 Characteristics of Included Patients, by Treatment Group 
 Glaucoma Follow-up Unit (n = 
405) 
Glaucoma Specialist (n = 
410) 
 n (%) n (%) 
Age (years) 
Mean ± SD 63.0 ± 12.1 63.1 ± 11.9 
Gender 
Women  218 (54) 214 (52) 
Follow-up time (months) 
Mean ± SD 9.8 ± 2.9 9.5 ± 2.9 
Intraocular pressure (mmHg) 
 Right eye Left eye Right eye Left eye 
Mean ± SD 18.68 ± 4.1 18.47 ± 4.1 18.76 ± 
4.2 
18.76 ± 4.1 
Target intraocular pressure (mmHg) 
 Right eye Left eye Right eye Left eye 
Mean ± SD 25.1 ± 5.2 25.2 ± 5.2 25.2 ± 5.4 25.1 ± 5.4 
HFA 
Mean Deviation ≤ -5 dB 34 (4) 34 (4) 
Medication 
No medication 172 (42) 182 (44) 
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3.1.1. Compliance of the GFU employees 
In table 1 we described the care GFU employees should provide according to the 
standard working protocol. A total of 853 visits were brought to the GFU. During 
those visits, almost every time (> 97.5%) the required tests were performed (table 4. 
1 Examinations). The only exception was the HFA. Thirty four patients of the GFU 
treatment group needed to be monitored with an HFA on a yearly basis, but 20 of 
these did not perform the test during the study period. In total 43 HFAs were 
performed in the GFU during the study period. Table 4.2 shows whether patients 
were referred back to the glaucoma specialist, as the protocol required. In 50% of the 
required cases they were not referred back to the glaucoma specialist. This mainly 
happened if the patient had a decline of visual acuity of 2 lines of more. 
 
Table 4 Compliance to the Standard Working Protocol by the Glaucoma Follow-up 
Unit Employees 
1. Examinations (n= 853) (%) 
Intraocular pressure 
 Right eye 850 (99.6) 
 Left eye 850 (99.6) 
Snellen visual acuity 
 Right Eye 847 (99.3)  
 Left Eye 843 (98.8) 
Optic Nerve 
 GDx ECC 832 (97.5) 
 HFA 43 (5.0)  
2. real / protocol required back referrals (%) 
Total 55 / 110 (50) 
 Reasons: 
Intraocular pressure > Target Intraocular 
pressure 
 
16 / 24 (66.7) 
 Snellen visual acuity decline of 2 lines or more 27 / 75 (36.0) 
 Suspicions of progression GDx ECC 23 / 25 (92.0) 
 Suspicion of progression HFA 3 / 4 (75.0) 
  
3.1.2. Care delivered by treatment group 
Every third visit of the patients assigned to the GFU treatment group was paid to a 
glaucoma specialist. We compared the care delivered by treatment group, this 
means that in the GFU treatment group the visits to the glaucoma specialist have 
been included. In table 5, the care delivered by treatment group has been compared. 
We were unable to detect any difference between the treatment groups with regard 
to the number of times the IOP was measured. In the GFU treatment group, the 
visual acuity and assessment of the optic disc (by GDx) was performed significantly 
more often than in the glaucoma specialist treatment group. Obviously, assessments 
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of the optic disc using the slitlamp occurred significantly more often by the glaucoma 
specialists than by the GFU HCPs, because these assessments were not required by 
the GFU protocol. The results of the various tests were not significantly different for 
the two study arms (Table 5.2).  
 
Table 5 Care delivered by Treatment Group (all visits are included) 
 Glaucoma Follow-up Unit (n= 
1181) 
Glaucoma specialists (n= 
919) 
P-value
1. Examinations (%) 
Intraocular pressure 
 Right eye 1171 (99.2) 911 (99.1) 0.953 
 Left eye 1171 (99.2) 911 (99.1) 0.953 
Visual Acuity 
 Right eye 994 (84.2) 626 (68.1) 0.000 
 Left eye 992 (84.0) 627 (68.2) 0.000 
Assessment of the 
Optic Nerve 
1130 (95.7) 849 (92.4) 0.001 
 of which 
- GDx ECC 
 
897 (76.0) 
 
429 (46.7) 
 
0.000 
 - HFA  71 (6.0) 71 (7.7) 0.121 
 - Slit lamp 306 (25.9) 774 (84.2) 0.000 
2. Results (%) 
Intraocular pressure > Target intraocular pressure  
 Right eye 88 / 1171 (7.5) 65 / 911 (7.1) 0.742 
 Left eye 89 / 1171 (7.3) 68 / 911 (7.5) 0.917 
Visual Acuity decline of 2 lines or more 
 Right eye 78 / 994 (7.8) 48 / 626 (7.7) 0.896 
 Left eye 86 / 992 (8.7) 46 / 627 (7.3) 0.340 
Suspicion of progression of the Optic Nerve 
 GDx ECC 41 / 881 (4.7) 27 / 420 (6.4) 0.179 
 HFA 11 /70 (15.7) 15 / 67 (22.4) 0.319 
  
3.1.3. Treatment changes 
The glaucoma therapy was changed during the study period in approximately 15 % 
of the patients; this happened approximately equally often in the 2 groups (Table 6).  
 
Table 6 Treatment changes by Treatment Group 
  Glaucoma Follow-up 
Unit (n= 405) 
Glaucoma specialists 
(n= 410) 
P-value 
At least one treatment change 57 (14.1) 63 (15.4) 0.603 
 Reasons: 
- Intraocular pressure 
 
44 / 87 (50.6) 
 
45 / 93 (48.3) 
 
0.769 
 - Optic Nerve (GDx ECC, 
HFA) 
13 / 87 (14.9) 16 / 93 (17.2) 0.680 
 - Intolerance to current 
medication 
19 / 87 (21.8) 17 / 93 (18.3) 0.551 
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3.1.4. Patient experiences 
We received 1492 questionnaires from the patients (response rate 71%).  
The patient experiences will be reported in 2 ways. Patients in the GFU group visited 
the GFU as well as the glaucoma specialists. We wanted to report per treatment 
group because it summarizes the experiences of patients per treatment method. In 
addition, we wanted to know what the experiences of the patients were per kind of 
HCP.  
In table 7, the experiences of the patients have been compared in several 
dimensions. We asked the patients to give an overall mark for the visit they paid in 
which a score of 1 was very bad and a score of 10 was very good. When comparing 
the HCPs, those of the GFU scored slightly higher than did the glaucoma specialists. 
Compared per treatment group, however, a similar difference did not reach statistical 
significance. The dimensions, knowledge, information, and waiting area had a scale 
of 1 (bad) to 4 (good). The GFU HCPs scored significantly lower than the glaucoma 
specialists on the dimensions knowledge and information. The questions about the 
courteousness of the HCPs were poorly filled-in by the patients. Patients were asked 
questions like; did the HCP provide support or did the HCP help you when you felt 
insecure or anxious? Did the HCP give sufficient information about what was going to 
happen? Because these questions were so poorly answered in the questionnaires, 
we have refrained from further analysing them.  
 
Table 7 Patient experiences 
  By Treatment group By HCP 
 Glaucoma 
Follow-up Unit 
(n) 
Glaucoma 
specialists 
(n) 
P-
value 
Glaucoma 
Follow-up Unit 
(n) 
Glaucoma 
specialists 
(n) 
P-
value
Overall mark (1-10) 8.50 (785) 8.42 (676) 0.147 8.56 (615) 8.40 (846) 0.006
± SD 1.05 1.15  1.02 1.15  
Knowledge (1-4)* 3.84 (698) 3.83 (625) 0.588 3.82 (539) 3.84 (784) 0.044
± SD 0.42 0.47  0.44 0.45  
Information (1-4)** 3.14 (655) 3.20 (577) 0.232 3.11 (511) 3.21 (721) 0.030
± SD 0.76 0.70  0.75 0.72  
Waiting area (1-4) 3.20 (621) 3.13 (584) 0.120 3.20 (486) 3.14 (719) 0.318
± SD 0.62 0.67  0.59 0.67  
* knowledge: did the HCP know about the patient’s disease and which test were 
needed? 
** information: did the patient know what was going to happen during the 
consultation? 
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3.2 Process Evaluation 
 
3.2.1. General comments 
The monitoring of the working process and the implementation showed that there 
were minor changes throughout the study period. The glaucoma specialists as well 
as the ophthalmic technicians said that the GFU was functioning satisfactorily. The 
GFU started late 2004. Today the GFU is structurally embedded in the REH. The 
glaucoma specialists are convinced the quality of care delivered at the GFU is 
guaranteed. The ophthalmic technicians enjoy working in the GFU. They appreciate 
the contact with the patients and the responsibility that monitoring of stable patients 
entails. On the other hand, the optometrist got little satisfaction out of the work. The 
optometrist called the work tedious. In the next section we will discuss the main 
findings of the process evaluation. 
 
3.2.2. Structure and capacity 
The GFU started in September 2004 with 2 clinics a week, which was swiftly 
expanded to 5 clinics a week. Currently, the GFU runs 7 clinics a week. In table 8, an 
overview of the number of patient visits is shown by the Glaucoma clinic (staffed by 
glaucoma specialists) and the GFU. 
 
Table 8. Number of patient visits 
Year Glaucoma 
clinic 
Glaucoma 
Follow-up Unit
Total 
2003 6405 0 6405 
2004 6283 14 6297 
2005 7716 572 8288 
2006 7447 1444 8891 
2007 8623 1598 10221 
2008 (until September) 6243 1390 7633 
 
The number of patient visits is increasing. According to the glaucoma specialists and 
the GFU HCPs, there are enough patients to expand the GFU to 10 clinics a week. 
At present, however, there is not enough manpower available to staff the GFU for 
more than 7 clinics a week. 
 
During the course of the study, there were a few personnel changes in the GFU. 
Initially, the 5 GFU clinics were staffed by 4 ophthalmic technicians and 1 
optometrist. The optometrist left the REH in October 2005. He was replaced by 
another optometrist. This optometrist left the GFU in October 2007. Her services 
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were needed elsewhere in the REH. She was not replaced by another optometrist, 
but by an ophthalmic technician. One ophthalmic technician left the GFU in 
December 2006, she was replaced by another ophthalmic technician. All glaucoma 
specialists working in the REH at the start of the study still worked as glaucoma 
specialist in the REH at the end of the study. No extra glaucoma specialist was taken 
on. 
 
Per consultation at the GFU, 20 minutes was scheduled, which also covered the 
taking of a GDx image. The consultation time has not been changed. If an HFA was 
required, a separate appointment had to be made. Almost all interviewed GFU 
employees mentioned that 20 minutes per patient was a bit tight in the beginning. 
Performing the tests was not a problem but talking with the patients turned out to be 
time consuming. Through experience, they learned to run the conversation more 
efficiently.   
 
3.2.3. Distribution of responsibilities 
There have been no changes in de distribution of responsibilities during the study 
period. The glaucoma specialists and GFU employees believed the distribution of the 
responsibilities was clear and needed no adjustments.  
 
3.2.4. Protocols  
The glaucoma specialists and employees of the GFU were all involved in formulating 
the protocols. 
The referral protocol for ophthalmologists to the GFU was not changed during the 
study period. At the start of the GFU, patients who did not meet the inclusion criteria 
were sent to the GFU regularly. Ophthalmologists received verbal feedback on their 
referral behaviour. Currently, almost all patients referred to the GFU meet the 
inclusion criteria.  
The standard working protocol of the GFU was satisfactory in almost every way. The 
visual acuity turned out to be difficult to capture in the protocol. Loss of visual acuity 
is usually not a sign of glaucomatous progression. Some issues were not well 
covered by the protocol, such as what ought to be done with patients with beginning 
cataract, or those requiring new glasses, or those with a frequently fluctuating visual 
acuity? According to the protocol, these patients had to be referred back to the 
referring ophthalmologist. This did not always happen. The interviewed glaucoma 
specialists were quite satisfied how the GFU employees acted in the spirit of the 
protocol, rather than to the letter.  
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An HFA was not always performed as required by the standard protocol. There were 
several reasons for these protocol violations. Firstly, patients were, mostly due to old 
age, not always able to perform the HFA any more. An HFA is generally far more 
exhausting to a patient than a GDx. Secondly, when ophthalmologists referred 
patients to the GFU with a follow-up time of 1 year, they were not always aware the 
patient required an HFA according to protocol and did not specifically request one. 
When the patient showed up at the GFU by appointment, it was not always possible 
to perform an unscheduled HFA, due to waiting lists.  
  
3.2.5. Monitoring / feedback 
All medical records of the first 200 patients visiting the GFU were checked by a 
glaucoma specialist. It turned out that virtually no mistakes had been made. 
Therefore the glaucoma specialist decided he would thereafter be checking medical 
records at random, about 1 out of every 10. Two other glaucoma specialists also 
wanted to check part of the medical records and asked the GFU employees to 
periodically keep a sample of them apart. One glaucoma specialist did not feel the 
need to check the work of the GFU. The ones who wanted to see some medical 
records did this whenever they deemed necessary. There were no formal meetings 
arranged between the GFU employees and the glaucoma specialists during the study 
period. Neither of the HCPs felt the need to.  
 
3.2.6. Implementation 
Although all glaucoma specialists were involved in formulating the protocols they 
were not all equally willing to refer patients to the GFU. Two glaucoma specialists 
started referring patients to the GFU from the start. A third glaucoma specialist was 
reluctant to refer any patients to the GFU. This glaucoma specialist generally gives 
the patients a relatively early next appointment to more closely control their follow-up. 
The GFU was considered a bridge too far, because it did not allow an equally close 
control of follow-up. Currently, this glaucoma specialist is referring more patients than 
before to the GFU. Because the experiences with the GFU have been positive over 
the years and positive interim results of the RCT, this glaucoma specialist has 
gradually become convinced that the quality of care provided by the GFU is 
sufficient. Another incentive to start referring ever more patients to the GFU was the 
increasing number of patients on the glaucoma specialist’s own clinic. It was 
becoming more and more difficult to make additional appointments for patients.  
A fourth glaucoma specialist initially refused to refer patients to the GFU. This 
glaucoma specialist’s main concern was not the quality of care delivered at the GFU 
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but the consequences of referring stable patients to the GFU could have on his own 
clinic, and the effect the GFU would have on his workload. This glaucoma specialist 
was afraid the referring of patients to the GFU would change his patient mix. He  
expected his clinic to become more difficult, more time-consuming. Today this 
glaucoma specialist refers patients to the GFU but only when the people who make 
the patient appointments remind him that his own clinics are already overbooked. He 
then browses through the medical records of many of his patients to determine which 
of these are suited for the GFU.  
Currently all four glaucoma specialists refer patients to the GFU, all at their own 
discretion. 
 
 
3.3 Economic Evaluation 
 
3.3.1. Study duration 
The randomization procedure per treatment group has been described in the method 
section. Patients who were randomized to glaucoma specialist treatment group on 
the day of their visit to the GFU, entered the study at their next visit (to the glaucoma 
specialist), whereas patients who were randomized to the GFU treatment group, 
entered the study immediately. Therefore, the mean study duration was longer for the 
GFU treatment than for the glaucoma specialist group. The mean study duration for 
the glaucoma specialist group was 1.43 year, ranging from 0.19 to 2.40 (SD= 0.35) 
and 1.81 year for the GFU group ranging from 0.12 to 2.50 (SD=0,50). This 
difference was statistically significant (p<0.001). Hence, for a better comparison, we 
will present the costs per patient per year in most tables. The costs per patient have 
been described in the text only.  
 
 3.3.2. Hospital perspective 
The hospital costs covered hospital visits, diagnostic procedures and further 
treatment, but were mainly driven by the costs of the hospital visits. There were 
different types of hospital visits: a visit to the glaucoma specialist, a visit to a resident, 
and three types of visits to the GFU, as there were three different types of personnel 
within the GFU. Per HCP, the duration of 10 study related visits was measured 
(Table 9). It also shows the composition of these unit costs per type of visit. The 
costs of a visit included (direct) personnel costs of the HCP, indirect personnel costs 
(e.g. the receptionist and outpatient administration) and overhead costs (e.g. building 
maintenance, management of the REH, the financial department and cleaning costs, 
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etc). Implementation costs of the GFU were added only to the GFU visits. They 
consisted of internal preparatory meetings, visits to another Dutch hospital, writing 
the standard working protocol and the training of the employees of the GFU. 
 
Table 9. The composition of the unit costs per type of hospital visit in € (2007) 
  Visit 
glaucoma 
specialist 
Visit 
resident 
Visit 
GFU 
MOA* 
Visit 
GFU 
TOA** 
Visit GFU 
Optometrist 
*** 
Costs per visit      
Total direct personnel costs 24.36 14.49 15.05 16.61 19.09 
Total indirect personnel 
costs 
5.46 5.46 6.59 6.59 6.59 
Total overhead costs 29.76 29.76 35.90 35.90 35.90 
Implementation costs GFU 0.00 0.00 3.08 3.08 3.08 
Total costs excluding 
GDx 
59.58 49.71 60.62 
 
62.18 64.66 
Costs GDx**** 
(fraction performed) 
25.00 
(0.41) 
22.25 
(0.36) 
3.05 3.05 3.05 
Total costs including GDx 84.58 71.96 63.67 65.23 67.71 
Mean visit duration in 
minutes 
9.06 11.00 20.40 20.40 20.40 
* Visit to a MOA (medical ophthalmic assistant) 
** Visit to an ophthalmic technician 
*** Visit to an optometrist or senior employee  
**** At the start of the GFU, a GDx was purchased by the REH. The costs of the 
GDx performed during GFU visits, consists only of the GDx imaging device. When 
performed in the glaucoma specialist group, the GDx was taken separately from the 
visit. In that situation, the costs of a GDx image included personnel and overhead 
costs as well and were €61.61 based on a duration of 13.30 minutes. 
 
The direct personnel costs were calculated based on the mean time spent on one 
visit as mentioned in table 9. However, the indirect personnel and overhead costs 
were calculated top-down, based on the mean duration of a visit in the hospital as a 
whole. The REH distinguishes first visits (per year) and follow-up visits. Taking into 
account the proportion of both types of visits per department, the indirect personnel 
costs and the overhead costs were based on a 9.03 minutes duration of a visit to the 
glaucoma specialist and resident and 10.89 minutes for a visit to the GFU. 
 
Patients within one treatment group could have different types of visits. In the 
glaucoma specialist treatment group, most visits were paid to the glaucoma specialist 
or resident. Patients in the GFU arm, visited the ophthalmologist at every third visit 
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and in case the patient was thought to have an unstable glaucoma. Therefore, the 
hospital visit costs per visit could vary within one patient and between patients within 
one treatment group. Because of the different types of visits within one treatment 
group, the mean costs per hospital visit including GDx were 83.77 (SD=30.64) in the 
glaucoma specialist group and €68.34 (SD=15.66) in the GFU group. This difference 
in mean costs per visit between the two treatment groups was statistically significant 
(t-test, p=0.000). 
 
Table 10 describes the hospital care use per patient per year for the two treatment 
groups. Although the number of visits per patient per year was higher in the GFU 
group, the difference between the two treatment groups was not statistically 
significant. In the glaucoma specialist group, significantly more appointments were 
made in the refractive unit, compared to the GFU group. On the other hand, a 
statistically higher number of auto-refractions were made in the GFU treatment 
group. The HCPs involved in the GFU also spent more time on asking advice.  
 
Table 10. Average hospital care use per patient year for both treatment groups  
  GFU Glaucoma 
specialist 
P-value Costs per unit (in €) 
Hospital visits 1.65 1.57 0.158 See Table 9 
GDx ECC 1.28 0.77 0.000 61.61 
HFA 0.10 0.11 0.266 158.44 
Refractive Unit  0.01 0.05 0.002 32.43 
Auto-refraction  0.20 0.08 0.000 4.64 - 6.59* 
Pachymetry 0.02 0.04 0.246 23.17 
IOP diurnal curve 0.01 0.02 0.109 92.66 
Asking advice 0.24 0.10 0.000 8.19 – 15.86** 
Laser treatment 0.002 0.007 0.267 78.38 
Glaucoma surgery 0.002 0.001 0.558 1251.70 
Patients using 
medication 
0.57 0.59 0.614 2.53 – 18.82*** 
*  Depending on HCP 
** Depending on HCP and advising HCP 
*** Costs per month  
 
The average hospital care utilization as described in Table 10, has been translated 
into costs per patient year for the two treatment groups in Table 11. The total hospital 
costs were significantly higher for the glaucoma specialist group than for the GFU 
group, mainly because of the higher hospital visits costs. The costs of asking advice 
were modest, but significantly higher for the GFU group than for the glaucoma 
specialist group, as was to be expected.  
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Table 11. Mean hospital costs in Euros per patient per year (SD) 
 GFU Glaucoma specialist  P-value 
Hospital visits (including GDx ECC) 111.93 (50.93) 133.17 (50.44) 0.000 
Other tests (HFA, refraction, pachymetry, etc) 20.66 (47.03) 24.18 (48.72) 0.001 
Laser treatment related to glaucoma 0.18 (2.54) 0.57 (5.18) 0.258 
Glaucoma surgery 2.84 (40.35) 1.72 (34.90) 0.558 
Asking advice 3.24 (5.35) 1.78 (5.13) 0.000 
Total hospital costs per patient per year 
 
138.85 (89.30) 
 
161.43 (86.88) 
 
0.000 
 
  
3.3.3. Patient perspective 
The patient costs consisted of time and travelling costs of patients and their 
accompaniment. Table 12 shows that the patient costs per visit were significantly 
higher in the glaucoma specialist group, because of higher time costs. This was 
mainly caused by a longer waiting time in the hospital and the higher number of 
patients with accompaniment in the glaucoma specialist group. Patients in the GFU 
group spent, on average, 44.6 minutes in the hospital against 59.4 minutes for the 
patients in the group of the ophthalmologist (p=0.000). The number of adults 
accompanying the patients was, on average, 0.25 vs. 0.29 in the GFU group and 
glaucoma specialist group, respectively (p=0.010).  
However, because of a higher number of visits per patient year in the GFU arm, the 
patient costs per patient year were not statistically significantly higher anymore. 
 
Table 12. Patient costs per visit and per patient year in Euros (SD) 
 GFU Glaucoma specialist  P-value  
Patient costs per visit    
Travelling costs of patient and accompaniment 8.26 (11.83) 8.19 (12.10) 0.966 
Time costs of patient and accompaniment 40.58 (28.87) 47.51 (34.36) 0.000 
Total patient costs per patient per visit 48.83 (33.68) 55.70 (37.88) 0.000 
Patient costs per patient year    
Travelling costs of patient and accompaniment 13.04 (17.16) 12.70 (17.87) 0.488 
Time costs of patient and accompaniment 66.62 (50.20) 75.17 (61.37) 0.088 
Total patient costs per patient per year 
 
79.66 (58.51) 
 
87.87 (68.17) 
 
0.143 
 
 
3.3.4. Health care perspective 
The health care costs consisted of the hospital costs as described above and the 
medication costs. Table 13 shows the health care costs per patient per year. Despite 
higher medication costs in the GFU arm, the total health care costs per patient per 
year were significantly higher for the glaucoma specialist group. 
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Table 13. Total health care costs per patient per year in Euros (SD) 
 GFU Glaucoma specialist  P-value 
Hospital costs  138.85 (89.30) 161.43 (86.88) 0.000 
Medication costs 91.54 (101.37) 89.82 (100.53) 0.867 
Total health care costs per patient per year 230.39 (154.57) 251.26 (146.02) 0.004 
 
 
3.3.5. Societal perspective  
In the societal perspective all costs were taken into account. Despite the limited 
difference in costs of less than 10%, the total (societal) costs per patient per year 
were significantly higher in the glaucoma specialist group (Table 14). The total costs 
per patient were €568.07 in the GFU group and €494.44 in the glaucoma specialist 
group (data not presented in Table 14). 
 
Table 14. Total societal costs per patient per year in Euros (SD) 
 GFU Glaucoma specialist  P-value 
Hospital costs  138.85 (89.30) 161.43 (86.88) 0.000 
Patient costs 79.66 (58.51) 87.87 (68.15) 0.143 
Medication costs 91.54 (101.37) 89.82 (100.53) 0.867 
Total societal costs per patient per year 310.05 (181.86) 339.13 (180.39) 0.009 
 
The mean difference in the total societal costs per patient year was -29 euro (the 
GFU treatment group was cheaper). The 95% confidence interval for this difference 
ranged from -54 to –4 euro. 
 
3.3.6. Sensitivity analysis 
We performed a sensitivity analysis to determine the effects of plausible policy 
changes in the (near) future on the costs per patient year (Table 15). We considered 
the following scenarios: 
1. No optometrists will be involved any longer in the GFU. This actually happened 
during the study. 
2. Because of an uncertainty in the duration of the visits as measured during this 
study, we varied the duration of the visits. The mean duration of the visit to the 
glaucoma specialist was 9.06 minutes, to the resident 11 minutes and to the GFU 
20.4 minutes. In this analysis we varied the duration of the visits from 7 to 11 minutes 
for the glaucoma specialist, from 9 to 13 minutes for the resident and from 16 to 24 
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minutes for the GFU visits. The variation was based on the range of durations 
measured in this study. 
a. all visit durations were shorter (7, 9 and 16 minutes respectively); 
b. all visit durations were longer (11, 13 and 24 minutes respectively); 
c. visits to the GFU group were shorter and visits to the glaucoma specialist group 
longer; 
d. visits to the glaucoma specialist group were shorter and visits to the GFU group 
longer. 
 
Table 15. Total average costs per patient year for all scenarios in the sensitivity 
analysis 
    Base 
case 
Scenario 
1 
Scenario 
2a 
Scenario 
2b 
Scenario 
2c 
Scenario 
2d 
GFU 138.85 135.16 117.79 156.79 117.79 156.79 
Specialist 161.43 159.47 141.80 179.98 179.98 141.80 
Hospital 
costs 
P-value 0.000 0.000 0.000 0.000 0.000 0.000 
GFU 79.66 79.66 79.66 79.66 79.66 79.66 
Specialist 87.87 87.87 87.87 87.87 87.87 87.87 
Patient 
costs 
P-value 0.143 0.143 0.143 0.143 0.143 0.143 
GFU 230.39 226.70 209.33 248.33 209.33 248.33 
Specialist 251.26 249.30 231.62 269.81 269.81 231.62 
Health 
care 
costs P-value 0.004 0.002 0.001 0.006 0.000 0.000 
GFU 310.05 306.36 289.00 328.00 383.23 452.3 
Specialist 339.13 337.17 319.49 357.68 434.64 379.99 
Societal 
costs 
P-value 0.009 0.006 0.005 0.010 0.000 0.000 
 
In all but the last sensitivity analysis, the costs per patient per year were significantly 
lower for the GFU treatment group than for the glaucoma specialist group. Only when 
the duration of a visit to the glaucoma specialist was relatively short (7 minutes) and 
the duration of a visit to the GFU was relatively long (24 minutes, scenario 2d), the 
costs per patient year were significantly higher in the GFU treatment group. 
 
 
3.4 Feasibility study 
 
The substitution of care to primary care optometrists does not seem feasible in the 
near future. Seven main findings support this conclusion. 
1. Glaucoma specialists did not adhere to the substitution in location. They approved 
the substitution of care to the GFU within the hospital, which reduced their workload. 
Furthermore, they welcomed the possibility to check the quality of care delivered by 
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the ophthalmic technicians. The physicians feared to lose control over their patients if 
they were to be referred to optometrists outside the hospital. 
2. Without the active support of physicians, most patients are unlikely to visit primary 
care optometrists for glaucoma monitoring. With more advanced visual field loss, 
they were probably more reluctant to visit primary care optometrists. They 
nevertheless admitted several advantages of the substitution of location, such as 
faster and more flexible appointments, a shorter travelling distance to the HCP, and 
the poor accessibility of the REH. 
3. Optometry is a fairly new and relatively unknown profession in the Netherlands. In 
addition, the degree of organisation of the OCR optometrists is still quite rudimentary. 
The OCR optometrists usually are self-employed. The OCR is therefore not as well 
organized as for example large optician chains. This weakens their position in 
discussing the substitution of care. Their role is therefore relatively passive. 
4. The health care insurers are reluctant to initiate discussions between optometrists 
and the REH about shared care. They are currently little driven to start discussing 
reimbursement of substituted care. If however, the REH can guarantee the quality of 
care, they will seriously consider reimbursements. 
5. Since the GFU was primarily run by ophthalmic technicians, not by optometrists 
who also worked in optic dispensaries, the bonds between the ophthalmic 
technicians and ophthalmologists tightened, strengthening mutual confidence, at the 
expense of and confidence in optometrists.  
6. Many GFU employees also took part in another project with optometrists. This 
collaboration gave the GFU employees insufficient confidence in the optometrists’ 
level of expertise. 
7. The REH has recently embarked on other collaborative projects with optometrists, 
thereby reducing the need to pursue shared glaucoma care, as an indirect means to 
consolidating, or even increasing, the inflow of patients. 
 
In table 16 a summary of the positions (support/opposition) and the power-positions 
of the stakeholders is shown. 
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Table 16 Summary of the stakeholders positions 
Stakeholders Support/opposition Power-position 
Primary care optometrists Strong support Low 
Glaucoma specialists Strong opposition High 
Patients Moderate support Medium  
Health Insurers Moderate support High  
REH management Moderate support Medium 
GFU employees Strong opposition Low 
 
On the other hand, some factors are in favour of the feasibility of the substitution of 
location. The primary care optometrists support the idea of substituting the 
monitoring of glaucoma patients to their stores. They were confident they could 
completely monitor stable glaucoma patients. The only skill they thought required 
extra training was the interpretation of GDx images. Those primary care optometrists 
that were already involved in another shared care project, i.e., into glaucoma 
screening with the GDx, did not think they required additional training, though. In that 
glaucoma screening project, a well functioning ICT platform had already been 
established, which could equally be used for the transfer of any medical information 
between the hospital and the optometrists’ stores. In our design of shared care, the 
GDx played an important role. It would have to be available in any such shared care 
project. In the screening project described earlier, all participating optometrists 
already had access to the GDx.  
Substituting the monitoring of stable glaucoma patients to optometrists’ stores would 
improve their image of professionalism, thereby strengthening their position in the 
commercial competition with others, notably the larger optic dispensary chains. To 
the optometrists’ dismay, there are currently no reimbursements for optometric 
examinations or care. In their shops, they are faced with a dilemma: they were 
trained to carry out optometric examinations, which are not reimbursed, whereas they 
have to make a living by selling glasses, which requires relatively few optometric 
skills. Without any appropriate reimbursements, monitoring (stable) glaucoma 
patients would be highly unprofitable.  
 
Since the substitution of location is improbable, we will not report about the 
Willingness to Accept (WTA) the substitution of care by the primary care optometrist.  
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4 Conclusions 
 
 
4.1 RCT and process evaluation 
 
The results of the RCT and process evaluation showed that the quality of care 
delivered by the GFU employees was comparable to the care delivered by the 
glaucoma specialists. Patients and HCPs were satisfied with the functioning of the 
GFU. The GFU standard working protocol worked well in most respects; for the 
visual acuity, however, it was too tight, which led to protocol violations that were 
deemed acceptable by GFU employees and ophthalmologists alike. For simplicity, 
the protocol was left unchanged. 
 
 
4.2 Economic Evaluation 
 
The costs of the GFU treatment group compared to glaucoma specialist group were 
significantly lower for three of the four perspectives used. Only the patient costs did 
not differ between the two treatment arms. Therefore, we can conclude that the 
substitution in person is cost-effective. The sensitivity analysis did confirm this cost 
effectiveness when varying the duration of the visits and when replacing the 
monitoring by optometrists with monitoring by other GFU employees. Only when 
reducing the duration of the visits in the glaucoma specialist group, while increasing 
the duration of the GFU treatment group, the total costs for the GFU treatment group 
were significantly higher compared to the glaucoma specialist group. 
 
 
4.3 Feasibility study 
 
The substitution of care to primary care optometrists (i.e., in person and location) did 
not seem feasible in the near future. In short, the GFU functioned to the satisfaction 
of the glaucoma specialists and other HCPs. They consequently did not feel the need 
to involve a third party, the primary care optometrist. Why change a winning team? 
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5 Discussion 
 
A main reason for establishing the GFU was the expected increase in the demand for 
glaucoma care in general, resulting from an aging population. The overall increase 
that we found in patients seeking glaucoma care in the REH further substantiated the 
need for shared care projects such as ours.  
A report by The Dutch College of Ophthalmologists (NOG, 2003)1, based on 
questionnaires amongst ophthalmologists, states that the policy of the college should 
be focused on allocating supporting personnel like optometrists and ophthalmic 
technicians.  
Little is known about the substitution of care in ophthalmology, the organizational and 
professional dynamics involved and its consequences for the quality of care and cost 
effectiveness. Substituting tasks within hospitals is currently taking place, but there 
has not been an extensive evaluation on the effects of this substitution. In the UK, 
there has been a long running study, including an RCT, on substituting care for 
stable glaucoma patients to primary care optometrists2-6 showing a similar quality of 
care provided by optometrists and glaucoma specialists.  
 
Although not all GFU employees were optometrists, we expected to find a similar 
quality of care in the two treatment groups. This turned out to be correct. The 
substitution of care to the GFU was succesfully implemented.  
1. The quality of care provided in the GFU was comparable with the care provided by 
the glaucoma specialists, for a subset of glaucoma patients, i.e., those that were 
deemed stable; 
2. The patients, GFU employees and the glaucoma specialists were pleased with the 
functioning of the GFU;  
3. The costs per patient per year were significantly lower for the patients visiting the 
GFU than for those visiting the glaucoma specialist;  
4. Since the start of the GFU, we have seen a yearly increase of glaucoma patients 
visiting the REH.   
The costs per visit in the GFU appeared to be lower than per visit to the glaucoma 
specialist. We expected this because of lower personnel costs of the GFU employees 
compared to glaucoma specialists. Based on the study of Druss7, we did not expect 
to save costs. Since substitution of care often results in a more annual visits because 
of a shorter follow-up time and extra (unnecessary) referrals to the specialist, the 
savings in personnel costs are often reduced. However, in our study the annual 
number of visits was not much larger compared to the usual care and the percentage 
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of referrals was just 6%. The total costs per patient per year turned out to be lower in 
the GFU group than in glaucoma specialist group.  
 
A limitation of our study is that we were not able to use glaucomatous progression as 
an outcome measure, for several reasons; (1) glaucoma typically runs a very slow 
course. We did not expect to be able to detect any glaucomatous progression in the 
30 months of our study period. To detect any glaucomatous progression over time, 
clinical trials typically run between 5 to 8 years. When the diagnosis of primary open 
angle glaucoma (POAG) is made, the average life expectancy is 13 to 16 years8; (2) 
moreover there is no general agreement on the best way to detect any glaucomatous 
progression of glaucomatous visual field loss.9 
  
In the unit costs of a visit in the REH used for the internal budget allocation, the 
overhead and general personnel costs were calculated per minute of monitoring. 
These were based on the total number of patient visits per year in the REH and the 
mean duration per visit. We were able to adjust the visit duration to the real duration 
for this specific group of patients. Most of the sensitivity analyses did not affect the 
cost-effectiveness of monitoring patients in the GFU. 
 
Although the substitution of care to the GFU was a success, our feasibility study 
showed that referring patients from the REH to primary care optometrists is currently 
not a realistic option. The success of the GFU was a reason for the REH to start 
other follow up units as well, such as a cornea follow-up unit staffed by optometrists. 
In addition, plans are under way to further expand shared care projects in the REH, 
involving other areas of (chronic) eye diseases.  
 
Currently, several hospitals participating in the Eye Care Network are interested in 
the concept of a GFU. These, as well as other hospitals outside the Eye Care 
Network, could benefit from our results when starting a GFU and use our referral 
criteria and standard working protocol. We used a GDx to judge the optic nerve, but it 
is also possible to use visual fields or other imaging devices. The standard working 
protocol should then of course be adjusted accordingly.   
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6 Recommendations 
 
 
6.1 Generic policy recommendation 
 
One has to decide who is to staff the GFU. In the REH, the ophthalmic technicians 
proved to be perfectly capable of monitoring stable glaucoma patients. They already 
were highly experienced with the GDx. The GFU was not staffed with primary care 
optometrists. If a hospital wants to expand the monitoring of stable glaucoma patients 
to optician stores, it is probably helpful to staff the GFU with primary care 
optometrists from the beginning. 
 
 
6.2 Practical recommendations 
 
1. An ophthalmologist should be made project manager of the GFU. The GFU in the 
REH would probably not have been a success without the close ties between the 
glaucoma specialist and the GFU. 
2. All ophthalmologists monitoring glaucoma patients should be involved in the 
formulation of the referral criteria and the standard working protocol. The criteria and 
protocol of the GFU in the REH could be used as guideline. 
3. GDx images are used in the GFU to judge the optic nerve. Not all hospitals own a 
GDx device. The ophthalmologists should decide which device they would like to 
use.  
4. Arrange extra training for the GFU employees as required. 
5. Check the medical records of patients monitored by the GFU. Start by checking all 
medical records and provide immediate feedback if required; when things run 
smoothly and accurately, downsize the checks to approximately 1 out of 10 medical 
records. A smaller proportion may perhaps function well enough to safeguard the 
quality of care. 
6. Plan the GFU clinics when ophthalmologists may answer any questions.  
7. Evaluate the referral criteria and the standard working protocol. In the beginning, it 
is sensible to do this more frequently, for example after 6 months. When the GFU 
runs satisfactorily, you could do this at greater time intervals of, for example, 3 years. 
8. Plan once yearly meetings with all involved ophthalmologists and GFU employees. 
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7 Appendix 1. Patient flow chart 
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